MedPal AI buys Remedi pharmacy assets for £310,000 and adds a second NHS dispensing hub
MedPal AI has bought the Remedi pharmacy business in Runcorn for total cash consideration of £310,000. On the face of it, that is the headline investors will care about – a relatively modest outlay for a pharmacy site that, according to NHS-verified data, dispensed 1 million prescription items in calendar year 2024.
The company says that level of activity equates to historical annualised turnover of approximately £10 million at current NHS average item values. That does not mean MedPal is suddenly banking £10 million of revenue tomorrow, but it does show why management sees this as a scale opportunity rather than a small bolt-on.
Strategically, this matters because MedPal now operates two NHS dispensing hubs – one in Swaffham and one in Runcorn – under a shared technology, clinical governance and commercial setup. In simple terms, the company is trying to spread its fixed cost base over a larger prescription volume and get its pharmacy arm to breakeven faster.
Why the Runcorn pharmacy acquisition matters for MedPal AI’s 80,000 items per month breakeven target
The key line in this RNS is not just the acquisition itself. It is management’s statement that the pharmacy business can reach EBITDA breakeven at a run rate of 80,000 items per month.
EBITDA is a rough operating profit measure before interest, tax and non-cash accounting charges. So when MedPal talks about pharmacy-level EBITDA breakeven, it is saying the pharmacy operation on its own could cover its operating costs once prescription volumes hit that level.
That target looks more credible because the company says the acquired Runcorn site dispensed over 100,000 items per month at its peak in 2024. Swaffham, by comparison, dispensed over 30,000 items per month at its own peak in 2024. March group volumes were over 40,000 items, and the CEO says the business is currently dispensing 42,000 items a month and rising.
Put bluntly, MedPal is trying to bridge the gap from roughly 42,000 items per month today to 80,000 items per month for pharmacy-level breakeven. If it can reactivate enough of Remedi’s former patient base and care home contracts, the maths starts to look a lot more interesting.
| Key figure | Amount |
|---|---|
| Total acquisition cost | £310,000 |
| Runcorn prescription items in 2024 | 1 million |
| Historical annualised turnover at current NHS average item values | Approximately £10 million |
| Peak monthly items at Runcorn in 2024 | Over 100,000 |
| Peak monthly items at Swaffham in 2024 | Over 30,000 |
| March group dispensing volume | Over 40,000 items |
| Current dispensing volume quoted by CEO | 42,000 items per month |
| Pharmacy-level EBITDA breakeven target | 80,000 items per month |
| NHS pharmacy gross margin | In excess of 34% |
How the Remedi deal was structured – and why the related party angle needs attention
This was not a simple one-step acquisition. Remedi had entered administration on 6 December 2024, and MedPal’s CEO, Jason Drummond, had previously entered into a conditional sale and purchase agreement in October 2025 to acquire the trade and assets.
He paid £30,000 to secure that right and also paid Castlebridge Finance Limited £250,000 to release security over Remedi’s assets. A further approximately £1,000 was spent setting up New Performance Health Limited, or NPH, which took a lease over new premises in Runcorn on 8 April 2026.
On 28 April 2026, MedPal Limited stepped into that agreement via a deed of novation. A novation is just a legal transfer of rights and obligations from one party to another. On completion, MedPal Limited reimbursed Mr Drummond’s total costs of £280,000 and paid the final £30,000 under the original agreement, taking total consideration to £310,000.
Because the CEO was involved personally before the company stepped in, this counts as a related party transaction under the AIM Rules. The independent directors, excluding Mr Drummond, said the terms are fair and reasonable after consulting the nominated adviser.
That does not automatically make it bad. In fact, management may argue the CEO helped secure an asset the company wanted. But investors should still clock the governance angle. When a chief executive is on both sides of a transaction chain, even if disclosed properly, it deserves a bit of extra scrutiny.
MedPal AI’s pharmacy strategy: reactivating patients, care homes and automation-led growth
The company is applying the same playbook it used after buying Universal Pharmacy assets in October 2025. That strategy includes getting patients to re-nominate MedPal as their chosen NHS pharmacy, winning back care home contracts, improving service levels with robotic dispensing, and tying it all into the MedPal app and MedPal Health OS.
That sounds sensible because pharmacy scale is often about repeat volumes, reliability and logistics. If MedPal can use automation and delivery to improve service, there is a genuine commercial argument for patient retention and reactivation.
The company says its robotic systems deliver approximately 99.9% accuracy and support 24/7 same-day and next-day delivery. That is a useful operational selling point, especially in care home dispensing where reliability matters a lot.
MedPal also says its wider businesses – MedPal.clinic, MedPal Health OS and at-home blood test kits – can support customer introductions and data sharing. The broad pitch is an integrated digital health platform rather than a stand-alone pharmacy. That could become a differentiator, although the RNS does not disclose revenue or profitability figures for those other divisions.
What looks positive in this MedPal AI RNS – and what still needs proving
What looks positive
- Price versus historic activity: £310,000 for access to a site with NHS-verified 2024 dispensing of 1 million items looks inexpensive on paper.
- Clear scale logic: Management has tied the acquisition directly to a stated breakeven threshold of 80,000 items per month.
- Evidence of prior capacity: Runcorn alone reportedly exceeded 100,000 items per month throughout 2024, which suggests the infrastructure has handled scale before.
- Operational momentum: Group dispensing volumes have already reached over 40,000 items per month, with the CEO quoting 42,000 currently.
What still needs proving
- Historic volume is not guaranteed volume: Remedi was in administration, so the big question is how much of that patient book can actually be retained or won back.
- Breakeven is pharmacy-level, not group-level: The RNS is careful here. Group profitability depends on more than the dispensing hubs.
- Limited financial detail: The company does not disclose current pharmacy EBITDA, cash balances, integration costs beyond the acquisition, or the lease economics for the new Runcorn site.
- Related party complexity: The structure may be fair, but it is still more complex than a straightforward third-party purchase.
My view on MedPal AI’s Remedi acquisition for retail investors
I think this is a positive RNS, mainly because it gives MedPal a believable route to scale in pharmacy without paying a huge upfront price. The company is not buying a dream here – it is buying a real dispensing operation with verified historical throughput and plugging it into an existing platform.
That said, investors should keep their feet on the ground. The value in this deal depends on execution, not on the historical 2024 numbers alone. Reactivating patients and care home contracts is the whole game.
If MedPal can push monthly volumes from 42,000 towards 80,000, the pharmacy business could start looking materially stronger. If it struggles to recapture the Remedi book, then the attractive acquisition price will not matter nearly as much as bulls hope.
So the simple takeaway is this: strategically smart, financially interesting, but still very much a prove-it story. The next updates on dispensing volumes will matter more than the acquisition headline itself.
